Drug intelligence / Profile preview

BRKB-400

Development stage: Preclinical
Lead developer: BrickBio
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules

Overview

BRKB-400 is an antibody-drug conjugate (ADC) under development by BrickBio for the treatment of neoplasms, specifically solid tumors. As an ADC, it consists of a monoclonal antibody linked to a cytotoxic agent designed to selectively target and kill cancer cells while sparing normal tissue. The drug is currently in preclinical development and has not yet entered clinical trials or received regulatory approval[8].

Beyond the preview

Go deeper on BRKB-400.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BRKB-400.

Explore the full profile